Sun Pharmaceutical Industries Limited — Financials & Forensics
Sector: Healthcare · NSE: SUNPHARMA · BSE: 524715 · ISIN: INE044A01036
18 Aug 2026
Add SUNPHARMA to your watchlist — all of this, automated.
Sign in with GoogleAnnual P&L snapshot
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue from operations | ₹38,654 Cr | ₹43,886 Cr | ₹48,497 Cr | ₹52,578 Cr | ₹58,462 Cr |
| EBITDA | ₹10,398 Cr | ₹11,647 Cr | ₹13,023 Cr | ₹15,272 Cr | ₹17,731 Cr |
| EBITDA margin | 26.9% | 26.5% | 26.9% | 29.1% | 30.3% |
| Profit after tax | ₹3,273 Cr | ₹8,474 Cr | ₹9,576 Cr | ₹10,929 Cr | ₹11,479 Cr |
Deeper analysis
Recent filings by Sun Pharmaceutical Industries Limited
-
Update on Lipitor Antitrust Litigation
17 Aug 2026 · Regulatory Compliance
-
Receipt of No-objection letters from the Stock Exchanges for Reclassification of Promoter Group
06 Aug 2026 · Regulatory Compliance
-
Analysts/Institutional Investor Meet/Con. Call Updates
06 Aug 2026 · Financial Results
-
Analysts/Institutional Investor Meet/Con. Call Updates
05 Aug 2026 · General Update
-
Update on Credit Rating
05 Aug 2026 · Regulatory Compliance
Never miss a filing again
About Sun Pharmaceutical Industries Limited on Indian Stock Alerts
Indian Stock Alerts tracks Sun Pharmaceutical Industries Limited's SEBI / exchange filings in real time. Every quarterly result, audited annual report, shareholding pattern update, insider trade and corporate announcement is automatically parsed and surfaced as a structured data point — with a link back to the underlying filing.
Data points refreshed daily include closing price, 1Y change, market cap, P/E, ROE, dividend yield, RPT volume, audit / governance / accrual flags. Quarterly results numbers refresh within minutes of the company filing them with BSE / NSE.